Tuberous Sclerosis Complex
📧 Sign up to get email alerts when something new happens for Tuberous Sclerosis Complex.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2015-05-07Clinical Trial Update: The Cognitive Variability in NF1 and TSC Monozygotic Twins
Clinical trial update examining cognitive variability in monozygotic twins with Neurofibromatosis Type I and Tuberous Sclerosis Complex.
-
CLINICAL_TRIALS trial_result · 2015-05-05Clinical Trial Update: Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex [Phase 2, Phase 3]
Phase 2/Phase 3 clinical trial evaluating the efficacy of everolimus (RAD001) for autism spectrum disorders and neuropsychological deficits …
-
CLINICAL_TRIALS trial_result · 2014-10-20Clinical Trial Update: Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex [Phase 1, Phase 2]
This clinical trial update reports results for everolimus (RAD001) therapy of giant cell astrocytoma in patients with tuberous sclerosis com…
-
FDA approval · 2014-07-01FDA Approved: AFINITOR DISPERZ — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application to add Afinitor Disperz, the dispersible tablet form of everolimus, expanding formulation options fo…
-
CLINICAL_TRIALS research · 2014-04-04Clinical Trial Update: Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex [NA]
A long-term prospective study evaluating clinical and molecular biomarkers of epileptogenesis in a genetic model of epilepsy related to tube…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA label_change · 2014-04-03FDA Approved: SABRIL — Supplemental Application (Lundbeck Pharmaceuticals LLC)
FDA approved a supplemental application for Sabril (vigabatrin) submitted by Lundbeck Pharmaceuticals LLC.
-
CLINICAL_TRIALS trial_result · 2013-09-25Clinical Trial Update: RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM [Phase 1, Phase 2]
A Phase 1/2 trial evaluated the mTOR inhibitor everolimus (RAD001) for angiomyolipomata in patients with tuberous sclerosis complex and spor…
-
CLINICAL_TRIALS trial_result · 2013-09-18Clinical Trial Update: Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM) [Phase 1, Phase 2]
Long-term follow-up results for everolimus (RAD001) therapy in patients with tuberous sclerosis complex-associated angiomyolipoma and sporad…
-
CLINICAL_TRIALS trial_result · 2012-08-28Clinical Trial Update: Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) [Phase 3]
Phase 3 trial assessing the efficacy and safety of everolimus (RAD001) in adults with angiomyolipoma associated with tuberous sclerosis comp…
-
CLINICAL_TRIALS trial_result · 2012-03-08Clinical Trial Update: Rapamycin In Angiomyolipomas In Patients With Tuberous Sclerosis [Phase 4]
Phase 4 clinical trial update on rapamycin (sirolimus) for angiomyolipomas in patients with tuberous sclerosis; the study has completed.
-
CLINICAL_TRIALS trial_result · 2012-02-27Clinical Trial Update: Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1) [Phase 1]
Phase 1 trial evaluating topical rapamycin for cutaneous manifestations of tuberous sclerosis complex and neurofibromatosis type 1 has compl…
-
CLINICAL_TRIALS trial_result · 2008-04-30Clinical Trial Update: Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM [Phase 2]
Phase 2 trial evaluating the efficacy and safety of sirolimus in tuberous sclerosis complex and lymphangioleiomyomatosis.
-
CLINICAL_TRIALS trial_result · 2007-04-09Clinical Trial Update: Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM [Phase 2]
Phase 2 clinical trial update reports on rapamycin therapy for patients with tuberous sclerosis complex and sporadic lymphangioleiomyomatosi…